-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Hepatitis B virus (HBV) is an important risk factor for patients with chronic hepatitis B (CHB) to develop hepatocellular carcinoma (HCC).
In 2016, there were approximately 880,000 HBV-related HCC deaths worldwide
In the past 20 years, the use of effective nucleotide analogs (ie reverse transcriptase inhibitors [NRTI]) has significantly changed the course of CHB.
This study aims to evaluate whether residual HBV viremia after NRTI treatment is related to the occurrence of HCC.
104 cases of patients treated with Entecavir (ETV) for at least 3 years, and Cobas Taqman method V2.
diagnosis
Detection of HBV DNA at the time of diagnosis of HCC
Detection of HBV DNA at the time of diagnosis of HCCAmong these 104 patients (male 80.
Serum DNA was not detected in 38.
Detection of HBV pgRNA at the time of diagnosis of HCC
Detection of HBV pgRNA at the time of diagnosis of HCCIt can be detected that HBV DNA and pgRNA are associated with the 2-year increased risk of HCC (hazard ratio [HR] 2.
It can be detected that HBV DNA and pgRNA are associated with an increased 2-year risk of HCC (hazard ratio [HR] is 2.
In patients with CHB standard method for detecting HBV DNA in below the LLOQ, detected by a more sensitive method, there is a continuing viremia found in up to 50% of patients related to HBV DNA or the occurrence of HCC pgRNA HBV DNA Or pgRNA is related to the occurrence of HCC
Original source:
Original source:Mak Lung-Yi,Huang Qi,Wong Danny Ka-Ho et al.
org/10.
1007/s00535-021-01780-5" target="_blank" rel="noopener">Residual HBV DNA and pgRNA viraemia is associated with hepatocellular carcinoma in chronic hepatitis B patients on antiviral therapy in this message
